Aging
Navigate
Research Paper|Volume 8, Issue 9|pp 2204—2221

Clinical significance and prognostic value of TRIM24 expression in esophageal squamous cell carcinoma

Jun Chi1,2,3,4, Qing Yang1,2,3,4, Xiao-Feng Xie1,2,3,4, Xian-Zi Yang2,3,4, Mei-Yin Zhang2,3,4, Hui-Yun Wang2,3,4, Guo-Liang Xu1,2,3,4
  • 1Department of Endoscopy and Laser, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China
  • 2State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China
  • 3Guangdong Esophageal Cancer Institute, Guangzhou 510060, China
  • 4Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
Received: May 18, 2016Accepted: September 12, 2016Published: September 28, 2016

Abstract

Tripartite motif-containing 24 (TRIM24), a member of the transcription intermediary factor 1 family, is defined as a co-regulator with several nuclear receptors, such as RARα. TRIM24 has been reported to be involved in many cancers. In this study, we aimed to investigate the expression pattern and prognostic significance of TRIM24 and its relationship with RARα in esophageal squamous cell cancer (ESCC). Both mRNA and protein expression levels of TRIM24 were found to be significantly decreased in ESCC, as judged by qRT-PCR and western blot. Immunohistochemistry staining shows that the reduced TRIM24 protein is associated with lymph node metastasis (P=0.024), advance pathological TNM (pTNM) stage (P=0.046) and recurrence/metastasis (P=0.001). Upregulated TRIM24 protein predicts longer overall survival and disease-free survival (both P<0.001) and is an independent predictor for good prognosis (HR, 0.519; 95%CI, 0.341-0.788; P=0.002). TRIM24 expression has been proven remarkably to improve prediction of survival of pTNM stage in ESCC patients, especially in stage I and II. However, no significant relationship was found between TRIM24 and RARα expression levels. In conclusion, reduced TRIM24 protein is associated with poor survival in ESCC patients, suggesting TRIM24 protein is a potential prognostic biomarker for ESCC.